Browsing Tag
U.S. Food and Drug Administration
129 posts
Why TEM stock sentiment could hinge on Tempus AI’s FDA-approved diagnostics expansion
Find out how Tempus AI’s xT CDx approval could strengthen TEM stock sentiment, oncology diagnostics growth, and ADLT pricing strategy.
Why Joenja’s pediatric expansion could strengthen Pharming Group’s long-term commercial runway
Find out how Pharming’s Joenja FDA review could affect PHAR stock sentiment, pediatric APDS access, and rare-disease revenue growth.
ImmunityBio targets U.S. BCG shortage with exclusive Tokyo-172 agreement and FDA pathway plan
BCG supply is still a U.S. bladder cancer bottleneck. ImmunityBio’s Tokyo deal could widen access, if regulators move with it.
Genentech secures first ctDNA MRD-guided therapy approval for Tecentriq in MIBC
A cancer drug win is only half the story. Roche and Natera are testing whether ctDNA can decide who truly needs treatment.
Atrium Therapeutics (Nasdaq: RNA) Q1 results show cash runway and clinical urgency behind precision cardiology bet
Atrium has cash and RNA ambition. The harder test is whether heart-targeted delivery can turn rare cardiomyopathy science into clinical proof.
Rznomics gets FDA RMAT status for RZ-001, but can one liver cancer signal carry a platform story?
RNA editing has a regulatory opening in liver cancer. Rznomics now must prove RZ-001 can turn FDA momentum into durable clinical value.
Harbour BioMed FDA IND clearance puts HBM7004 into the clinical spotlight as bispecific oncology race intensifies
Harbour BioMed has FDA clearance, but HBM7004 must now prove whether its B7H4xCD3 design can translate platform science into clinical value.
The a2 Milk Company recalls U.S. infant formula batches as cereulide detection sparks market sell-off
The a2 Milk Company faces investor scrutiny after a U.S. infant formula recall. Read how the risk could affect brand trust and strategy.
The a2 Milk Company recalls U.S. infant formula batches as cereulide risk raises supply-chain questions
Infant formula trust is fragile. The a2 Milk Company recall shows how one ingredient risk can become a wider supply-chain test.
Why Arcutis Biotherapeutics, Inc. is targeting infant eczema with ZORYVE cream
Can ZORYVE cream unlock infant eczema markets? Discover how Arcutis Biotherapeutics, Inc. is reshaping dermatology strategy today.